With the wide spread of multidrug-resistant bacteria, a variety of aminoglycosides have been
used in clinical practice as one of the effective options for antimicrobial combinations …

Resistance of Acinetobacter baumannii to multiple clinically important antimicrobials has
increased to very high rates in Greece, rendering most of them obsolete. The aim of this …

Background The clinical-stage drug candidate EBL-1003 (apramycin) represents a distinct
new subclass of aminoglycoside antibiotics for the treatment of drug-resistant infections. It …

Background Apramycin is under development for human use as EBL-1003, a crystalline free
base of apramycin, in face of increasing incidence of multidrug-resistant bacteria. Both …

Objectives Novel therapeutics are urgently required for the treatment of carbapenem-
resistant Acinetobacter baumannii (CRAB) causing critical infections with high mortality …

Aminoglycoside antibiotics are powerful bactericidal therapeutics that are often used in the
treatment of critical Gram-negative systemic infections. The emergence and global spread of …

Objectives New drugs and methods to efficiently fight carbapenem-resistant gram-negative
pathogens are sorely needed. In this study, we characterized the preclinical …

Following the observation of an increased number of isolation of OXA-23-and ArmA-
producing Acinetobacter baumannii at the national level, our aim was to evaluate whether …

Objectives To evaluate the in vitro activity of the combination of apramycin with colistin,
meropenem, minocycline or sulbactam, against some well-characterized XDR Acinetobacter …

Acinetobacter baumannii (Ab) has increasingly been identified as a cause of hospital-
acquired infections and epidemics. The rise of carbapenem-resistant Acinetobacter …